Antigen-specific tolerization approaches in multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 9-20

  Lutterotti, Andreas ^a   Martin, Roland ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antigen specific; Multiple sclerosis; T cell; Tolerance

Indexed keywords

APL CGP 77116; ATX MS 1467; AUTOANTIGEN; BETA1A INTERFERON; BHT 3009; CENTRAL NERVOUS SYSTEM AGENTS; DIRUCOTIDE; DNA VACCINE; IMILECLEUCEL T; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEIN; NEUROVAX; PEPTIDE VACCINE; PLACEBO; PROTEOLIPID PROTEIN; RTL 1000; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CUTANEOUS DRUG ADMINISTRATION; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOTHERAPY; MUCOSAL ADMINISTRATION; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ANIMALS; ANTIGENS; HUMANS; IMMUNE TOLERANCE; MULTIPLE SCLEROSIS;

EID: 84889836707     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.844788     Document Type: Review

References (85)

1. Steinman L. Inverse vaccination, the opposite of jenner's concept, for therapy of autoimmunity. J Intern Med 2010;267(5):441-51
2. Dolgin E. The inverse of immunity. Nat Med 2010;16(7):740-3
3. Lutterotti A, Sospedra M, Martin R. Antigen-specific therapies in ms-current concepts and novel approaches. J Neurol Sci 2008;274(1-2):18-22
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747 (Pubitemid 40563183)
5. Goverman JM. Immune tolerance in multiple sclerosis. Immunol Rev 2011;241(1):228-40
6. Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305-34 (Pubitemid 37174534)
7. Jenkins MK, Mueller D, Schwartz RH, et al. Induction and maintenance of anergy in mature t cells. Adv Exp Med Biol 1991;292:167-76
8. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific t cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165(2):302-19 (Pubitemid 17019817)
9. Krummel MF, Allison JP. Ctla-4 engagement inhibits il-2 accumulation and cell cycle progression upon activation of resting t cells. J Exp Med 1996;183(6):2533-40 (Pubitemid 26192363)
10. Walunas TL, Lenschow DJ, Bakker CY, et al. Ctla-4 can function as a negative regulator of t cell activation. Immunity 1994;1(5):405-13
11. Fife BT, Bluestone JA. Control of peripheral t-cell tolerance and autoimmunity via the ctla-4 and pd-1 pathways. Immunol Rev 2008;224:166-82
12. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010;11(1):21-7
13. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human t lymphocytes. J Exp Med 1995;181(1):71-7
14. Kabelitz D, Janssen O. Antigen-induced death of t-lymphocytes. Front Biosci 1997;2:d61-77
15. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11(1):14-20
16. Rudensky AY. Regulatory t cells and foxp3. Immunol Rev 2011;241(1):260-8
17. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory t cells and immune tolerance. Cell 2008;133(5):775-87 (Pubitemid 351707693)
18. von Boehmer H, Daniel C. Therapeutic opportunities for manipulating t(reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013;12(1):51-63
19. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007;7(9):665-77 (Pubitemid 47327394)
20. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37 (Pubitemid 24140432)
21. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-59 (Pubitemid 41105174)
22. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259(5099):1321-4 (Pubitemid 23100270)
23. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide mbp8298 delayed disease progression in an hla class ii-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13(8):887-95 (Pubitemid 44124687)
24. Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope p85 vvhffknivtp96 in chronic progressive multiple sclerosis. J Neurol Sci 1997;152(1):31-8 (Pubitemid 27469708)
25. Freedman MS, Bar-Or A, Oger J, et al. A Phase III study evaluating the efficacy and safety of mbp8298 in secondary progressive ms. Neurology 2011;77(16):1551-60
26. Goodkin DE, Shulman M, Winkelhake J, et al. A Phase I trial of solubilized dr2:mbp84-102 (ag284) in multiple sclerosis. Neurology 2000;54(7):1414-20 (Pubitemid 30210458)
27. Yadav V, Bourdette DN, Bowen JD, et al. Recombinant t-cell receptor ligand (rtl) for treatment of multiple sclerosis: a double-blind, placebo-controlled, Phase I, dose-escalation study. Autoimmune Dis 2012;2012:954739
28. Vandenbark AA, Rich C, Mooney J, et al. Recombinant tcr ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in hla-dr2 transgenic mice. J Immunol 2003;171(1):127-33 (Pubitemid 36745280)
29. Available from: http://Www.Apitope. Com/pipeline/ms.Html
30. Walczak A, Siger M, Ciach A, et al. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol 2013 Sep 1;70(9):1105-9
31. Jurynczyk M, Walczak A, Jurewicz A, et al. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 2010;68(5):593-601
32. Nicholson LB, Greer JM, Sobel RA, et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995;3(4):397-405
33. Windhagen A, Scholz C, Hollsberg P, et al. Modulation of cytokine patterns of human autoreactive t cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995;2(4):373-80
34. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat Med 2000;6(10):1167-75
35. Crowe PD, Qin Y, Conlon PJ, Antel JP. Nbi-5788, an altered mbp83-99 peptide, induces a t-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000;48(5):758-65
36. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 t helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The altered peptide ligand in relapsing ms study group. Nat Med 2000;6(10):1176-82
37. Ho PP, Fontoura P, Platten M, et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/il-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005;175(9):6226-34 (Pubitemid 41508112)
38. Ho PP, Fontoura P, Ruiz PJ, et al. An immunomodulatory gpg oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003;171(9):4920-6 (Pubitemid 37310616)
39. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled Phase I/II trial. Arch Neurol 2007;64(10):1407-15 (Pubitemid 47572664)
40. Garren H, Robinson WH, Krasulova E, et al. Phase II trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63(5):611-20
41. Papadopoulou A, von Felten S, Traud S, et al. Evolution of ms lesions to black holes under DNA vaccine treatment. J Neurol 2012;259(7):1375-82
42. Roep BO, Solvason N, Gottlieb PA, et al. Plasmid-encoded proinsulin preserves c-peptide while specifically reducing proinsulin-specific cd8+ t cells in type 1 diabetes. Sci Transl Med 2013;5(191):191ra182
43. Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000;107(2):130-9 (Pubitemid 30347418)
44. Hafler DA, Cohen I, Benjamin DS, Weiner HL. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992;62(3):307-13
45. Hermans G, Medaer R, Raus J, Stinissen P. Myelin reactive t cells after t cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000;102(1):79-84
46. Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein autoreactive t cells by t-cell vaccination: pilot trial in multiple sclerosis. Lancet 1995;346(8978):807-8
47. Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous csf-derived activated t cells: results from a pilot study. Clin Exp Immunol 2003;131(1):155-68 (Pubitemid 36098836)
48. Zhang J, Medaer R, Stinissen P, et al. Mhc-restricted depletion of human myelin basic protein-reactive t cells by t cell vaccination. Science 1993;261(5127):1451-4 (Pubitemid 23334267)
49. Fox E, Wynn D, Cohan S, et al. A randomized clinical trial of autologous t-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012;18(6):843-52
50. Loftus B, Newsom B, Montgomery M, et al. Autologous attenuated t-cell vaccine (tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol 2009;131(2):202-15
51. Achiron A, Lavie G, Kishner I, et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 2004;113(2):155-60 (Pubitemid 39296848)
52. Karussis D, Shor H, Yachnin J, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PLoS ONE 2012;7(12):e50478
53. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with t-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996;2(10):1109-15 (Pubitemid 26338630)
54. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent t cell receptor peptide vaccine for multiple sclerosis. Mult Scler 2005;11(5):552-61 (Pubitemid 41387700)
55. Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent t-cell receptor (tcr) peptide vaccine restores deficient foxp3 expression and tcr recognition in subjects with multiple sclerosis. Immunology 2008;123(1):66-78 (Pubitemid 350255999)
56. Braley-Mullen H, Tompson JG, Sharp GC, Kyriakos M. Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells. Cell Immunol 1980;51(2):408-13 (Pubitemid 10153399)
57. Dua HS, Gregerson DS, Donoso LA. Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells. Cell Immunol 1992;139(2):292-305
58. Fife BT, Guleria I, Gubbels Bupp M, et al. Insulin-induced remission in new-onset nod mice is maintained by the pd-1-pd-l1 pathway. J Exp Med 2006;203(12):2737-47 (Pubitemid 44833349)
59. Gregorian SK, Clark L, Heber-Katz E, et al. Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis. Cell Immunol 1993;150(2):298-310 (Pubitemid 23290334)
60. Karpus WJ, Pope JG, Peterson JD, et al. Inhibition of theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol 1995;155(2):947-57
61. Kennedy KJ, Smith WS, Miller SD, Karpus WJ. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: A comparison between oral and peripheral tolerance. J Immunol 1997;159(2):1036-44 (Pubitemid 127484261)
62. Kennedy MK, Tan LJ, Dal Canto MC, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990;144(3):909-15 (Pubitemid 20065030)
63. Miller SD, Claman HN. The induction of hapten-specific t cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol 1976;117(5 Pt 1):1519-26
64. Miller SD, Tan LJ, Kennedy MK, Dal Canto MC. Specific immunoregulation of the induction and effector stages of relapsing eae via neuroantigen-specific tolerance induction. Ann N Y Acad Sci 1991;636:79-94
65. Miller SD, Wetzig RP, Claman HN. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 1979;149(3):758-73 (Pubitemid 9137687)
66. Pope L, Paterson PY, Miller SD. Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in lewis rats. J Neuroimmunol 1992;37(3):177-89
67. Tan LJ, Kennedy MK, Dal Canto MC, Miller SD. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J Immunol 1991;147(6):1797-802
68. Turley DM, Miller SD. Peripheral tolerance induction using ethylenecarbodiimide-fixed apcs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 2007;178(4):2212-20 (Pubitemid 46233419)
69. Kohm AP, Turley DM, Miller SD. Targeting the tcr: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in cns autoimmune disease. Int Rev Immunol 2005;24(5-6):361-92 (Pubitemid 41755153)
70. Smarr CB, Hsu CL, Byrne AJ, et al. Antigen-fixed leukocytes tolerize th2 responses in mouse models of allergy. J Immunol 2011;187(10):5090-8
71. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells-a Phase I trial in multiple sclerosis. Sci Transl Med 2013;5(188):188ra75
72. Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by pd-l1 + and il-10-producing splenic macrophages and maintained by t regulatory cells. J Immunol 2011;187(5):2405-17
73. Raiotach-Regue D, Grau-Lopez L, Naranjo-Gomez M, et al. Stable antigen-specific t-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012;42(3):771-82
74. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17(2):210-18 (Pubitemid 46466140)
75. Goebels N, Hofstetter H, Schmidt S, et al. Repertoire dynamics of autoreactive t cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000;123(Pt 3):508-18 (Pubitemid 30099536)
76. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997;99(7):1682-90 (Pubitemid 27163819)
77. Tuohy VK, Yu M, Yin L, et al. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999;13(1):11-20 (Pubitemid 29367002)
78. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182(1):75-85
79. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2(2):85-95 (Pubitemid 37323232)
80. Bielekova B, Sung MH, Kadom N, et al. Expansion and functional relevance of high-avidity myelin-specific cd4+ t cells in multiple sclerosis. J Immunol 2004;172(6):3893-904 (Pubitemid 38337977)
81. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-12 (Pubitemid 39626806)
82. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88 (Pubitemid 351240747)
83. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel kir4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23
84. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32(6):758-66
85. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of mri in detecting disease activity in multiple sclerosis. Brain 1993;116(Pt 5):1077-94 (Pubitemid 23329882)